Key result
New-onset atrial fibrillation in patients undergoing neoadjuvant chemoradiation and esophagectomy was associated with significantly increased mortality and ventricular fibrillation (p<0.05).
Why the study?
Does new-onset atrial fibrillation increase mortality and cardiovascular risks in patients with esophageal cancer undergoing neoadjuvant concurrent chemoradiation and esophagectomy?
Observational
Does new-onset atrial fibrillation increase mortality and cardiovascular risks in patients with esophageal cancer undergoing neoadjuvant concurrent chemoradiation and esophagectomy?
p-value: p=<0.05
New-onset atrial fibrillation following neoadjuvant chemoradiation and esophagectomy for esophageal cancer is associated with significantly increased mortality and ventricular fibrillation.
This illustrates the outcomes of patients with esophageal cancer undergoing neoadjuvant concurrent chemoradiation and esophagectomy, specifically focusing on those who develop new-onset atrial fibrillation (NOAF). Statistically significant findings (p < 0.05, dark red) increased mortality and ventricular fibrillation, as well as trends of (p > 0.05, light red) myocardial infarction and pericardial effusion among NOAF patients. The data emphasize the significant cardiovascular risks associated with NOAF in this population.
No takes yet. Share an insight, caveat, or question.
Byer et al. (2025) conducted an observational in Esophageal cancer. New-onset atrial fibrillation (NOAF) vs. No NOAF was evaluated on Mortality and ventricular fibrillation (p=<0.05). New-onset atrial fibrillation in patients undergoing neoadjuvant chemoradiation and esophagectomy was associated with significantly increased mortality and ventricular fibrillation (p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: